Hematology Advisor

Hematology Advisor Hematology Advisor is a free online resource that offers healthcare professional the tools to assist in making the right decisions for their patients.

Operating as usual

#FDA approved Onureg® for the continued treatment of adult patients with #AML who achieved complete remission with incom...
09/04/2020
Oral AML Therapy Onureg Gets FDA Approval - Hematology Advisor

#FDA approved Onureg® for the continued treatment of adult patients with #AML who achieved complete remission with incomplete blood count recovery following intensive induction #chemotherapy and who are not able to complete intensive curative therapy. http://ow.ly/C6Cx50BihDR

The FDA has approved Onureg® (azacitidine; Bristol Myers Squibb) tablets for the continued treatment of adult patients in first remission with AML.

The number of prior novel agents administered or their use immediately prior to alloHCT for the treatment of #CLL was no...
09/03/2020
Prior Use of Novel Agents Does Not Affect alloHCT Outcomes in CLL - Hematology Advisor

The number of prior novel agents administered or their use immediately prior to alloHCT for the treatment of #CLL was not associated with outcomes, according to results of a retrospective study published in Blood Advances. http://ow.ly/88DP50Bh6Uj

Novel agents such as certain small-molecule inhibitors have generally improved outcomes among patients with CLL, but a subset still experience progression.

Documentation of survivorship discussions between adolescent and young adult #lymphoma survivors and their #oncologists ...
08/31/2020
Trends Suggest More AYA Lymphoma Survivors Being Engaged in Survivorship Discussions, But Improvements Needed - Hematology Advisor

Documentation of survivorship discussions between adolescent and young adult #lymphoma survivors and their #oncologists is improving, but information for survivors and their PCPs is still suboptimal.
http://ow.ly/KSt350BdI99

This retrospective study examined the medical charts of AYA lymphoma survivors for evidence of discussions with their oncologist regarding late effects of treatment.

Researchers developed a personalized prediction model, based on genes commonly mutated in myeloid malignancies, to predi...
08/27/2020
Personalized Prediction Model for Outcomes After Allogeneic HSCT for Myelodysplastic Syndromes - Hematology Advisor

Researchers developed a personalized prediction model, based on genes commonly mutated in myeloid malignancies, to predict survival and relapse probabilities for patients with MDS after allo-HSCT. #Hematology http://ow.ly/XgrF50BaKcZ

Identifying patients with myelodysplastic syndromes who may or may not benefit from HSCT is an important clinical need, as complications are common.

Address

275 7th Ave, 10th Fl
New York, NY
10001

Alerts

Be the first to know and let us send you an email when Hematology Advisor posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Hematology Advisor:

About Us

Hematology Advisor is a free online resource that offers hematology healthcare professionals a comprehensive knowledge base of practical hematology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform hematology decisions.

Nearby media companies